ANGLE plc (AIM: AGL)
Market Cap | 37.90M |
Revenue (ttm) | 2.19M |
Net Income (ttm) | -20.13M |
Shares Out | 322.53M |
EPS (ttm) | -0.08 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,200,840 |
Open | 11.61 |
Previous Close | 11.75 |
Day's Range | 11.07 - 11.74 |
52-Week Range | 9.07 - 37.40 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Sep 26, 2024 |
About ANGLE
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumera... [Read more]
Financial Performance
In 2023, ANGLE's revenue was 2.19 million, an increase of 109.99% compared to the previous year's 1.04 million. Losses were -20.13 million, -7.17% less than in 2022.
Financial StatementsNews
![](https://cdn.benzinga.com/files/images/story/2024/08/22/untitled_1.jpeg?optimize=medium&dpr=1&auto=jpg&height=480&width=720&fit=crop)
What's Going On With Plug Power Stock Today?
Plug Power, Inc. (NASDAQ: PLUG) shares are trading lower on Thursday. According to Benzinga Pro , PLUG stock has lost over 74% in the past year. Investors can gain exposure to the stock via Global X ...
![](https://cdn.snapi.dev/images/v1/a/f/press18-2602885.jpg)
Angle PLC - Data Supporting FDA Approval Published in Journal
DATA SUPPORTING FDA APPROVAL PUBLISHED IN HIGH-IMPACT JOURNAL Publication of results from ANGLE's Parsortix PC1 system validates use of Parsortix System for CTC isolation and harvest in metastatic bre...
![](https://cdn.snapi.dev/images/v1/j/t/press12-2530855.jpg)
Angle PLC Announces Standard Form for Notification of Major Holdings
GUILDFORD, SURREY / ACCESSWIRE / July 18, 2024 / TR-1: TR-1:Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microso...
![](https://cdn.snapi.dev/images/v1/x/y/press3-2519914.jpg)
Angle PLC Announces Result of 2024 Annual General Meeting
GUILDFORD, SURREY / ACCESSWIRE / July 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today...
![](https://cdn.snapi.dev/images/v1/p/q/press16-2484577.jpg)
Angle PLC Announces Posting of 2023 Annual Report & Notice of the AGM
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use...
![](https://cdn.snapi.dev/images/v1/r/r/press2-2472576.jpg)
Angle PLC Announces Parsortix and Assays being Showcased at EACR 2024
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH ANGLE presenting two posters highlighting the utility of CTC & ctDNA dual analys...
![](https://cdn.snapi.dev/images/v1/2/p/press6-2462887.jpg)
Angle PLC Announces Preliminary Results
Preliminary Results for the year ended 31 December 2023 COMMERCIALISATION BUILDING, WITH REVENUE MORE THAN DOUBLED New products and services launched; and breakthrough studies completed on combined ct...
![](https://cdn.snapi.dev/images/v1/n/f/press15-2433999.jpg)
Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix
INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian cance...
![](https://cdn.snapi.dev/images/v1/z/y/press13-2408446.jpg)
Angle PLC Announces New Commercial Agreement with Large Pharma
ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE / May 3, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a ...
![](https://cdn.snapi.dev/images/v1/t/i/press12-2387265.jpg)
Angle PLC Announces New Commercial Agreement with AstraZeneca
ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE / April 24, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a wo...
![](https://cdn.snapi.dev/images/v1/q/9/press13-2382332.jpg)
Angle PLC Announces US and EU Patents for Innovative CellKeep(TM) Slide
Proprietary cell recovery device and method eliminates over 70% of CTC cell loss from standard microscopy techniques increasing assay sensitivity GUILDFORD, SURREY / ACCESSWIRE / April 22, 2024 / ANGL...
![](https://cdn.snapi.dev/images/v1/j/r/press8-2360261.jpg)
Angle PLC Announces Parsortix HER2 Assay Showcased at AACR 2024
PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCE CTC HER2 assay being developed for HER2 targeted drugs and antibody drug conjugates presented at internationally renowned ...
![](https://cdn.snapi.dev/images/v1/f/x/press3-2336827.jpg)
Angle PLC Announces Parsortix at European Breast Cancer Conference
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCE ANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Por...
![](https://cdn.snapi.dev/images/v1/w/w/press2-2237710.jpg)
Angle PLC Announces Potential Utility in Precision Oncology
REVIEW PAPER ON MOLECULAR ANALYSIS OF PARSORTIX CTC HARVEST HIGHLIGHTS POTENTIAL UTILITY IN PRECISION ONCOLOGY Paper published in the journal "Current Issues in Molecular Biology" special issue: advan...
![](https://cdn.snapi.dev/images/v1/z/z/press12-2215801.jpg)
Angle PLC Announces Breakthrough Clinical Results
BREAKTHROUGH CLINICAL RESULTS PROVIDE A UNIQUE INSIGHT INTO THE PROGRESSION OF EACH PATIENT'S CANCER Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample highlights pot...
![](https://cdn.snapi.dev/images/v1/a/5/press1-2212722.jpg)
Angle PLC - Contract announcement with Eisai Inc.
Pilot study for ANGLE's Portrait HER2 assay in Phase II study of HER2 targeting antibody-drug conjugate, BB-1701 GUILDFORD, SURREY / ACCESSWIRE / January 2, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a ...
![](https://cdn.snapi.dev/images/v1/b/1/press20-2190540.jpg)
Angle PLC Announces Broker Announcement
GUILDFORD, SURREY / ACCESSWIRE / December 11, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use ...
![](https://cdn.snapi.dev/images/v1/w/1/press1-2190541.jpg)
Angle PLC Announces Parsortix Unlocks Opportunities for Drug Discovery
USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG DISCOVERY Harvested CTCs reveal gene expression profile associated with development and progression of brain metastasis in ...
![](https://cdn.snapi.dev/images/v1/i/p/press20-2183027.jpg)
ANGLE launches Portrait+ CTC kit at SABCS
ANGLE LAUNCHES PORTRAIT+ CTC KIT AT SAN ANTONIO BREAST CANCER SYMPOSIUM ANGLE's Portrait+ CTC staining kit combines the power of Parsortix® technology with an optimised immunofluorescent assay The tes...
![](https://cdn.snapi.dev/images/v1/4/g/press14-2148960.jpg)
Angle PLC Announces Trading and Business Update
Revenue recognised for 2023 expected to be up 120% at c. £2.2 million with sales secured in 2023 expected to be c.
![](https://cdn.snapi.dev/images/v1/s/b/press15-2148961.jpg)
Angle PLC Announces Launch of PD-L1 Test to Support Cancer Studies
ANGLE LAUNCHES PD-L1 TEST TO SUPPORT CANCER THERAPY STUDIES ANGLE's Portrait PD-L1 test uses CTCs harvested from the Parsortix system to investigate real-time patient PD-L1 status for clinical studies...
![](https://cdn.snapi.dev/images/v1/s/f/press5-2119042.jpg)
Angle PLC Announces Supporting characterisation of CTCs in HNSCC
RESEARCH DEMONSTRATES POTENTIAL OF THE PARSORTIX SYSTEM TO SUPPORT POWERFUL CHARACTERISATION OF CTCS IN HEAD AND NECK CANCER 41 key biomarkers including the immune checkpoint proteins PD-L1, CTLA4 and...
![](https://cdn.snapi.dev/images/v1/e/j/press9-2086949.jpg)
Angle PLC Announces Parsortix Outperforms Standard for DTC Harvest
PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST DTCs linked to cancer relapse even after prolonged remission DTCs harvested by the Parsortix system were '...
![](https://cdn.snapi.dev/images/v1/d/q/press16-2083148.jpg)
Angle PLC Announces Parsortix System Showcased at ACTC Conference
PARSORTIX SYSTEM SHOWCASED AT 'ADVANCES IN CIRCULATING TUMOR CELLS' CONFERENCE Nine poster presentations utilising the Parsortix system in six cancer types all received positive feedback GUILDFORD, SU...
![](https://cdn.snapi.dev/images/v1/h/o/press3-2052877.jpg)
Angle PLC Announces Interim Results for the Period Ended 30 June 2023
Interim Results for the six months ended 30 June 2023 BUILDING COMMERCIAL MOMENTUM DELIVERS REVENUE GROWTH Cash runway extended into Q1 2025 GUILDFORD, SURREY / ACCESSWIRE / September 7, 2023 / ANGLE ...